Literature DB >> 21235417

Host response cytokine signatures in viral and nonviral acute exacerbations of chronic obstructive pulmonary disease.

Raquel Almansa1, Monica Sanchez-Garcia, Agueda Herrero, Sergio Calzada, Vicente Roig, Julia Barbado, Lucia Rico, Felipe Bobillo, Jose M Eiros, Veronica Iglesias, Raul Ortiz de Lejarazu, Jesus F Bermejo-Martin.   

Abstract

Viruses are strongly associated with acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Interferon-inducible protein-10 has been recently described as a biomarker of human rhinovirus infection, but there are no reports on the role of other immune mediators in AECOPD of viral origin. As an attempt to evaluate the differences in the systemic immune mediators profiles between AECOPD patients with presence/absence of viral infection, we measured 27 cytokines, chemokines, and cellular growth factors in the plasma of 40 patients with AECOPD needing of hospitalization by using a Luminex-based assay. These patients were screened for the presence of 16 different respiratory viruses in pharyngeal swabs. Ten healthy controls were recruited for comparison purposes. Both the group of patients with an associated viral infection (n = 11) and those with no viral infection (n = 29) showed high levels of vascular endothelial growth factor, interleukin-13 (IL-13), and IL-2. On the other hand, viral infection in AECOPD induced a coordinated response of innate immunity chemokines (eotaxin, interferon-inducible protein-10, IL-8), Th1 cytokines (IL-12p70, IL-15), and the immunomodulatory IL-10. This profile corresponds to a typical antiviral response signature previously documented for other viral infections. The identification of early cytokine signatures associated with viral infection in AECOPD could contribute to design better treatment strategies for this disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21235417     DOI: 10.1089/jir.2010.0131

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  16 in total

Review 1.  The influence of virus infections on the course of COPD.

Authors:  H Frickmann; S Jungblut; T O Hirche; U Groß; M Kuhns; A E Zautner
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2012-09-10

2.  Magnitude and Quality of Cytokine and Chemokine Storm during Acute Infection Distinguish Nonprogressive and Progressive Simian Immunodeficiency Virus Infections of Nonhuman Primates.

Authors:  Sheila M Keating; John W Heitman; Shiquan Wu; Xutao Deng; Andrea R Stacey; Roland C Zahn; Maurus de la Rosa; Samantha L Finstad; Jeffrey D Lifson; Michael Piatak; Marie-Claire Gauduin; Benedikt M Kessler; Nicola Ternette; Angela Carville; R Paul Johnson; Ronald C Desrosiers; Norman L Letvin; Persephone Borrow; Philip J Norris; Joern E Schmitz
Journal:  J Virol       Date:  2016-10-28       Impact factor: 5.103

Review 3.  The role of viral infections in exacerbations of chronic obstructive pulmonary disease and asthma.

Authors:  Richard Hewitt; Hugo Farne; Andrew Ritchie; Emma Luke; Sebastian L Johnston; Patrick Mallia
Journal:  Ther Adv Respir Dis       Date:  2015-11-26       Impact factor: 4.031

4.  Prevalence and risk of viral infection in patients with acute exacerbation of chronic obstructive pulmonary disease: a meta-analysis.

Authors:  Xiaodong Wu; Du Chen; Xiaoling Gu; Xin Su; Yong Song; Yi Shi
Journal:  Mol Biol Rep       Date:  2014-04-02       Impact factor: 2.316

Review 5.  The Aryl Hydrocarbon Receptor as a Modulator of Anti-viral Immunity.

Authors:  Maria Florencia Torti; Federico Giovannoni; Francisco Javier Quintana; Cybele Carina García
Journal:  Front Immunol       Date:  2021-03-05       Impact factor: 7.561

6.  Serum IFN-γ-induced protein 10 (IP-10) as a biomarker for severity of acute respiratory infection in healthy adults.

Authors:  Mary S Hayney; Kelsey M Henriquez; Jodi H Barnet; Tola Ewers; Heather M Champion; Sean Flannery; Bruce Barrett
Journal:  J Clin Virol       Date:  2017-03-16       Impact factor: 3.168

7.  Quantification and role of innate lymphoid cell subsets in Chronic Obstructive Pulmonary Disease.

Authors:  Evy E Blomme; Sharen Provoost; Elise G De Smet; Katrien C De Grove; Hannelore P Van Eeckhoutte; Joyceline De Volder; Philip M Hansbro; Matteo Bonato; Marina Saetta; Sara Ra Wijnant; Fien Verhamme; Guy F Joos; Ken R Bracke; Guy G Brusselle; Tania Maes
Journal:  Clin Transl Immunology       Date:  2021-06-05

8.  Effect of lianhuaqingwen capsules on airway inflammation in patients with acute exacerbation of chronic obstructive pulmonary disease.

Authors:  Liang Dong; Jing-Wen Xia; Yi Gong; Zhen Chen; Hai-Hua Yang; Jing Zhang; Jian He; Xiao-Dong Chen
Journal:  Evid Based Complement Alternat Med       Date:  2014-05-25       Impact factor: 2.629

Review 9.  Cytokine inhibition in the treatment of COPD.

Authors:  Gaetano Caramori; Ian M Adcock; Antonino Di Stefano; Kian Fan Chung
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-04-28

10.  Xuan Bai Cheng Qi formula as an adjuvant treatment of acute exacerbation of chronic obstructive pulmonary disease of the syndrome type phlegm-heat obstructing the lungs: a multicenter, randomized, double-blind, placebo-controlled clinical trial.

Authors:  Miao Liu; Xianggen Zhong; Yuhang Li; Fengjie Zheng; Ruohan Wu; Yan Sun; Jinchao Zhang
Journal:  BMC Complement Altern Med       Date:  2014-07-11       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.